Inovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).
Drugs in Pipeline
7
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
INO Earnings Report
EPS Est: $-0.25 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How INO's past catalysts played out
VGX-3100
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
INO-4700
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
INO-3107
Respiratory Papillomatosis
INO-5401
Glioblastoma
INO-3112
Head and Neck Squamous Cell Cancer
INO-9012
Urothelial Carcinoma
VGX 3100
Cervical Intraepithelial Neoplasia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VGX-3100 | Phase 3 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | - | - |
INO-4700 | Phase 2 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | - | - |
INO-3107 | Phase 2 | Respiratory Papillomatosis | - | - |
INO-5401 | Phase 2 | Glioblastoma | - | - |
INO-3112 | Phase 2 | Head and Neck Squamous Cell Cancer | - | - |
INO-9012 | Phase 2 | Urothelial Carcinoma | - | - |
VGX 3100 | Phase 2 | Cervical Intraepithelial Neoplasia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Inovio Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Inovio Pharmaceuticals, Inc.'s (INO) pipeline across Phase 3, Phase 2. Its lead program is VGX-3100 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Inovio Pharmaceuticals, Inc.'s next FDA catalyst?→
Inovio Pharmaceuticals, Inc.'s (INO) next tracked catalyst is a Offering expected July 29, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INO biotech catalysts?→
Add INO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Inovio Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.